Skip to content

Treatment with supplementary L-ornithine in patients with pressure ulcers.

Treatment with supplementary L-ornithine in patients with pressure ulcers. - L-ornithine ingestion for pressure ulcers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012216
Enrollment
10
Registered
2013-11-05
Start date
2012-01-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pressure ulcer

Interventions

Food containing 2.5 g of L-ornithine per day (ORNUTE
KYOWA HAKKO BIO CO., LTD., Tokyo, Japan) was administered for 8 weeks by orally or enterally, twice daily (morning and evening).

Sponsors

Kurume University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: *The Omuta Memorial Hospital (Fukuoka, Japan) inpatients with Shea's Pressure Sores Classification grade 2 and more *Patients from whom or whose legal representative written informed consent is obtained

Exclusion criteria

Exclusion criteria: *Patients with history of high hypersensitivity *Patients with renal disease who is inadequate for the study *Patients with following conditions which may affect the blood albumin level irrelevantly to nutritional status -Malignancy -Acute inflammatory diseases such as infectious disease -Serious hepatic disorders such as cirrhosis -Severe burn or injury -History of metabolic disorders of amino acid *Patients at risk of acquiring allergy related the study *Patients with remarkable higher or lower laboratory values or physiological measurement than reference value *Patients included in other clinical studies within 3 months or in process *Patients with other conditions which principal investigator consider inadequate such as routine users of similar food (e.g. amino acid supplement)

Design outcomes

Primary

MeasureTime frame
DESIGN-R score, blood prealbumin, blood retinol-binding protein, blood transferrin, urinary 3-methyl-histidine

Countries

Japan

Contacts

Public ContactKimio Asagiri

Kurume University School of Medicine Department of Pediatric Surgery, Kurume University School of Medicine

asagiri@med.kurume-u.ac.jp+81-942-31-7631

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026